A model of Penn’s new approach using DQ661 to target PPT1, which inhibits both mTOR and autophagy
PHILADELPHIA – Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to target that enzyme resistant to treatment. Researchers were able to use this finding to develop a drug that successfully inhibits tumor growth of melanoma as well as pancreatic and colorectal cancer in mice. The journal Cancer Discovery published the findings
online this month.
The target is an enzyme called PPT1, which controls both the mechanistic target of rapamycin (mTOR), a major regulator of growth in cancer cells, as well as a process called autophagy, a built-in resistance mechanism which allows cells to survive when under attack by breaking down unneeded parts and recycling them to stay alive. Numerous drugs that target mTOR are approved by for cancer patients by the U.S. Food and Drug Administration, but targeting mTOR with these currently available inhibitors turns on autophagy, thus making the tumor resistant.
“What we learned in this study is that mTOR and autophagy aren’t opposed to each other as previously thought. They’re actually complementary, because autophagy provides the nutrients that allow mTOR to direct growth, while mTOR shuts off autophagy when the nutrients aren’t needed,” said co-senior author Ravi K. Amaravadi, MD, an associate professor of Hematology Oncology in the Perelman School of Medicine at the University of Pennsylvania and a member of Penn’s Abramson Cancer Center.
That yin and yang relationship takes place in a part of the cell called the lysosome. Previously, it has taken two drugs to stop both processes, but by focusing on drugs that hone in on the lysosome more efficiently, researchers have found one drug that can block both.
“We know that autophagy is an important mechanism for cancer resistance, but there are very few ways to block it. This is the first targeted approach to inhibiting the lysosome in order to block autophagy,” Amaravadi said.
The drug that makes it work is called DQ661, and it specifically targets the PPT1 enzyme that controls both mTOR and autophagy. This study suggests drugs that target PPT1 in this way could one day improve outcomes for cancer patients. DQ661 is a dimeric form of the antimalarial drug quinacrine – meaning it has two molecules of quinacrine bound together with a special linker.
“It turns out that both what is linking them and how they are linked are crucial to why this works,” said the study’s co-senior author Jeffrey D. Winkler, the Merriam Professor of Chemistry in the School of Arts and Sciences at the University of Pennsylvania. “In this study, we were able to tailor the chemistry so that the drug specifically targets PPT1 in the lysosome.”
The lead authors of the study were Vito W. Rebecca, PhD, a postdoctoral researcher in Amaravadi’s lab, Michael C. Nicastri, a graduate student in Winkler’s lab, and Noel McLaughlin, PhD, who was a postdoctoral researcher in Winkler’s lab at the time of the research. Winkler says the ability to work across multiple disciplines is what led to the discovery.
“As (Amaravadi) and his team tried to solve the autophagy problem, they came to us for help in developing a better form of quinacrine, which is what we have in DQ661,” Winkler said.
While the approach has clear clinical benefits, researchers still need to develop these compounds into drugs that are suitable for human patients, which will be the focus of their efforts moving forward.
This research was supported by the National Institutes of Health (R01CA169134, P01 CA114046, P30 CA016520, SPORE P50 CA174523, 1R01CA198015, CA016672, P30CA010815).
Editor’s Note: Amaravadi and Winkler have applied for a patent for DQ661.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.